The 2021 cohort of digital health companies was built for a public market exit. Most of them will not get one, and the ones that did have spent the years since trading well below their listing price and, in several cases, being taken private again.
That is not a temporary market condition to wait out. It is the structure of the sector, and it should change how companies are built.
Why the public path narrowed
Public investors learned three things from the last cycle.
Digital health revenue quality varies enormously. Contracts that looked recurring turned out to be annual and terminable. Enrolment-based revenue proved volatile with employer benefit cycles. Some of the most celebrated growth stories were selling into an employer channel with high churn and a long sales cycle, which is a hard combination to model.
Gross margin is often software-shaped in the deck and services-shaped in reality. Any model that includes clinician labour in the delivery has a cost structure that scales with revenue, and public comparables price that closer to a health services multiple than a software one.
Regulatory and reimbursement dependency introduces variance that public markets discount heavily. A single coverage decision can reset a forecast.
The result is a small number of digital health names that clear the public bar and a long queue that does not.
Who is buying, and what they underwrite
Three buyer types now set the price, and each values different things.
Strategic acquirers in health services and payers buy capability that plugs into an existing member or patient base. They underwrite the incremental margin on their own population, which means your standalone growth rate matters less than your fit with their book. They pay for a differentiated clinical model, contracted revenue, and clean regulatory posture. They discount heavily for customer concentration inside their competitors.
Platform consolidators, often private-equity backed, buy revenue they can integrate and de-duplicate. They underwrite cost synergies and cross-sell. They pay on a multiple of earnings, not revenue, which is the single most important sentence in this article for founders running at deliberate losses. They will model your business at their target margin and pay for the version they can create, not the version you have.
Larger technology and device companies buy distribution and data assets. They pay the widest range of prices, because they are occasionally buying strategic positioning rather than financials, but those deals are rare and cannot be planned for.
What that means about how you build
Contracted revenue quality beats growth rate. A company growing moderately on multi-year enterprise contracts with meaningful minimums will clear a higher price than a faster-growing company on annual, terminable agreements. Every renewal negotiation is therefore an enterprise-value decision, not an account-management task.
Know your gross margin honestly, and know it by cohort. Buyers will rebuild it. Clinical labour, implementation cost, support and data acquisition all belong above the line. A company that presents a software margin and gets recut to a services margin in diligence loses both price and credibility.
Concentration is a discount, and so is the wrong customer. Heavy revenue concentration with one payer or one system caps your buyer universe, because it makes you unattractive to their competitors. Diversification is a valuation activity, not just a risk-management one.
Data rights are an asset only if they are unencumbered. Many companies discover in diligence that their most valuable dataset is contractually owned by the customer or restricted from secondary use. That is worth checking now, while contracts are still being written, rather than in a data room.
Regulatory and compliance hygiene is priced. Clean clearance documentation, a defensible model governance file, complete business associate agreements and a clean security audit history remove diligence risk. Buyers pay for the absence of surprises more reliably than they pay for upside.
The reframe
None of this is pessimism. The last cycle mispriced a real sector, and the correction has been painful but rational. Healthcare will continue absorbing technology, budgets will continue shifting toward it, and durable companies are being built right now, quietly, on unglamorous contracted revenue.
What has changed is the buyer. Building for a public listing means optimising growth. Building for an acquisition means optimising contracted revenue quality, honest margin, and clean diligence. Those are genuinely different companies, and the founders who choose deliberately do considerably better than the ones who default to the pitch deck they read in 2021.
